ADC Therapeutics
Dr. van Berkel has more than 20 years of experience in the biotech industry, specializing in the development of antibody-based therapeutics.
Prior to joining ADC Therapeutics, Dr. van Berkel spent more than 9 years with Genmab in various roles, including Vice President of Antibody Technology and Vice President of CMC R&D.
Dr. van Berkel has a chemistry degree from the University of Nijmegen, The Netherlands (1991), and did his thesis at the University of Leiden, The Netherlands (1998).
This person is not in any offices
ADC Therapeutics
2 followers
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.